Labor Market Pulse · Life Sciences · September 2026
Life Sciences Labor Market Report: Longview, TX MSA — September 2026
Longview unemployment rises, but scientific talent scarcity doesn't follow.
Longview MSA unemployment climbed to 5.3% in June while Research Scientist advertised pay rose to $125,310 locally, still trailing the $131,354 national median and signaling scarcity decoupled from broader labor slack.
Free archive edition. Published by WageScape as sent to subscribers; data as of September 2026.
Key indicators
- Longview MSA unemployment rate: 5.3% — Up from 4.3% in March 2026
- Texas life sciences employer growth: 21.6% — Since 2019, outpacing talent pipeline growth
- Longview nonfarm payrolls: 123,900 — Aug 2026, +300 monthly, +0.6% annual
- Texas pharma subsector wage avg: $123,068 — 56.2% employer growth since 2019
Key takeaways
Metro unemployment up, specialist scarcity unchanged.
Longview's unemployment rate rose from 4.3% to 5.3% between March and June 2026, but this slack concentrates in lower-skill occupations, not the credentialed scientific and regulatory roles life sciences employers compete for statewide.
Research Scientist pay climbs locally but still trails national rate.
Metro median advertised pay for Research Scientist reached $125,310, up significantly year-over-year but still $6,000 below the national median of $131,354 — a gap that may widen further if Houston's biomanufacturing buildout pulls senior scientific talent out of smaller Texas metros.
Clinical Research Associate pay signals a tightening pipeline.
Advertised CRA pay rose significantly both locally ($81,374) and nationally ($90,956), consistent with sustained clinical trial activity competing for a limited credentialed pool — a trend that should inform whether CRO partnerships or in-house clinical ops hiring better absorbs near-term cost increases.
Houston's manufacturing surge is a regional talent magnet, not just a Houston story.
Eli Lilly's $6.5B and Bristol Myers' $2.3B Generation Park facilities create over 600 new jobs each, raising the realistic recruiting radius for quality and manufacturing specialists that Longview-based employers may have assumed were locally available.
Median advertised pay by role — Longview, TX MSA
| Role | 25th percentile | Median advertised pay | 75th percentile | Metro trend | National median |
|---|---|---|---|---|---|
| Research Scientist * | $84,986 | $125,310 | $136,499 | Significant increase | $131,354 |
| Clinical Research Associate * | $58,220 | $81,374 | $98,325 | Significant increase | $90,956 |
| Lab Technician * | $37,740 | $45,314 | $49,226 | Stable | $47,402 |
| Regulatory Affairs Specialist * | $70,793 | $95,949 | $116,373 | Moderate decline | $104,000 |
| Clinical Data Manager * | $96,493 | $122,953 | $136,780 | Stable | $123,031 |
| Biostatistician * | $104,135 | $141,493 | $163,775 | Significant increase | $133,322 |
| Validation Engineer * | $82,458 | $105,350 | $113,458 | Significant increase | $108,377 |
* State-level figure shown where metro postings were too few.
WageScape's median is calibrated to correct for spurious low-value postings (reported as the 60th percentile of raw advertised pay). Download: CSV · JSON
Local market conditions
Longview MSA unemployment climbed to 5.3% in June 2026 from 4.3% in March, even as nonfarm payrolls edged up to 123,900 by August, pointing to a labor market adding jobs slowly while labor supply loosens. Manufacturing and healthcare remain the metro's largest employment bases, but neither shows the acceleration seen in Houston's biomanufacturing corridor or statewide construction and professional services growth, leaving Longview-based life sciences employers reliant on a shallow local specialist pool.
What it means
Rising metro unemployment alongside flat-to-soft payroll growth suggests Longview life sciences employers face less wage pressure on general lab and support roles than peer Texas metros, but credentialed scientific, quality, and regulatory talent remains scarce regardless of local slack — these roles draw from a statewide or national pool, not the Gregg County labor force. Build-vs-outsource calculus should account for the fact that Houston's Lilly and Bristol Myers manufacturing expansions are pulling experienced operators and quality specialists toward Generation Park, potentially widening the recruiting radius and cost needed to retain comparable talent in Longview. Consider reviewing whether current compensation for regulatory and senior research roles reflects statewide competition rather than local market softness.
Looking ahead
Expected: BLS will release September 2026 Longview MSA unemployment and payroll data in mid-to-late October — watch whether the June-to-August softening trend continues, which would support more aggressive local hiring for non-credentialed roles.
Emerging pressure point: Houston's biomanufacturing expansion (Lilly, Bristol Myers at Generation Park) is scaling through 2026-2027; track whether Longview-based quality and manufacturing specialists are recruited away, which would tighten an already thin regional bench.
Worth watching: National biopharma layoffs (BioMarin, Bristol Myers Squibb) are concentrated in consolidation functions, not execution roles — monitor whether any displaced regulatory or CMC talent enters the Texas candidate pool via relocation.
Early indicator: San Jacinto College's NIBRT-licensed biotech training center, now a year into operation, may begin producing technician-level graduates — watch whether this eases Lab Technician hiring pressure in East Texas before it affects higher-credential roles.
Methodology
Advertised pay from active employer job postings, not survey data. WageScape's median is calibrated to correct for spurious low-value postings: distribution analysis shows roughly the lowest 10% of raw values are erroneous entries, so the reported median is the 60th percentile of raw advertised pay. WageScape observes 98% of U.S. job openings daily.
Free to read and cite with attribution to WageScape. Terms of use.